Cardiotoxicity in patients treated with mitoxantrone: Southwest Oncology Group phase II studies.
A model describing the development of cardiotoxicity as a function of cumulative dose of a drug and other covariates is presented. Methods are given for testing and illustrating a cumulative dose effect. Also, equations for estimation of the probability of developing cardiotoxicity in the presence or absence of competing risks are given. The methods are illustrated for mitoxantrone by means of data obtained from Southwest Oncology Group studies.